Idorsia Ltd (SWX:IDIA)
Switzerland · Delayed Price · Currency is CHF 4.504
-0.058 (-1.27%)
Oct 2, 2026, 1:32 PM CET
Idorsia Revenue
Idorsia had revenue of 52.86M CHF in the quarter ending June 30, 2026, a decrease of -26.83%. This brings the company's revenue in the last twelve months to 199.71M, down -8.06% year-over-year. In the year 2025, Idorsia had annual revenue of 220.58M with 96.06% growth.
Revenue (ttm)
199.71M
Revenue Growth
-8.06%
P/S Ratio
6.15
Revenue / Employee
437.97K
Employees
487
Market Cap
1.23B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.58M | 108.08M | 96.06% |
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 708.53M |
| Basilea Pharmaceutica AG | 247.42M |
| Santhera Pharmaceuticals Holding AG | 101.50M |
| Newron Pharmaceuticals | 9.62M |
| BioVersys AG | 4.62M |
| MindMaze Therapeutics Holding | 1.20M |
| Molecular Partners AG | 681.00K |
| Xlife Sciences AG | 397.23K |
Idorsia News
- 18 days ago - Idorsia price target raised to CHF 6 from CHF 5 at H.C. Wainwright - TheFly
- 1 month ago - Idorsia price target raised to CHF 5.50 from CHF 4.50 at Deutsche Bank - TheFly
- 2 months ago - Idorsia Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Idorsia Quarterly report: Q2 2026 - Filings
- 2 months ago - Idorsia Earnings release: Q2 2026 - Filings
- 2 months ago - Idorsia Slides: Q2 2026 - Filings
- 2 months ago - Idorsia Slides: Company presentation - Filings
- 3 months ago - Idorsia price target raised to CHF 4.50 from CHF 4 at Deutsche Bank - TheFly